{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-029936","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2024-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.464947+00:00","generated_at":"2026-05-31T01:58:35.370849+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"medium","headline":"Windtree announces positive Phase 2b topline results for istaroxime in early cardiogenic shock","bullets":["Istaroxime met primary endpoint: significantly improved systolic blood pressure profile over six hours vs placebo.","Significant improvements in many secondary endpoints; safety profile favorable, consistent with prior trials.","Study tested two dosing regimens (decreasing and constant) over up to 60 hours infusion to optimize late-stage design.","Detailed results to be presented at Heart Failure Society of America on Sept 30, 2024; investor call planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-029936","json":"https://secwatch.observer/filing/0001437749-24-029936.json","markdown":"https://secwatch.observer/filing/0001437749-24-029936.md","text":"https://secwatch.observer/filing/0001437749-24-029936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774924029936/0001437749-24-029936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774924029936/wint20240924c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:58:35.370849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}